Orris

15m Precocious puberty,classification and its management 5m Pseudohernaphroditism Evaluation of secondary amennorhea MTP act

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
I now have comprehensive material from authoritative textbooks. Let me compile the full answer.

Precocious Puberty - Classification and Management (15 marks)

Definition

Precocious puberty is the onset of secondary sexual characteristics before 8 years in girls and 9 years in boys, with associated acceleration of linear growth and bone age advancement.
  • In girls: 20x more common than in boys; ~90% are idiopathic
  • In boys: only ~10% are idiopathic; a CNS cause must always be sought

Classification

I. Gonadotropin-Dependent (Central / True Precocious Puberty)

Activation of the hypothalamic-pituitary-gonadal (HPG) axis causes pulsatile LH/FSH release, which drives gonadal hormone production. It is always isosexual (consistent with the child's phenotypic sex).
Causes:
  1. Idiopathic (majority in girls)
  2. CNS tumors - hypothalamic hamartoma (most common structural cause), optic glioma, astrocytoma, ependymoma, tuberous sclerosis, arachnoid cysts
  3. Inflammatory/infectious CNS lesions
  4. Gene mutations regulating GnRH secretion - kisspeptin (KISS1), kisspeptin receptor (KISS1R), MKRN3
  5. Prior CNS irradiation or trauma

II. Gonadotropin-Independent (Peripheral / Pseudo-Precocious Puberty)

Sex steroids are produced independent of pituitary gonadotropin stimulation. LH/FSH are suppressed. Can be isosexual or heterosexual.
Causes in girls:
  1. McCune-Albright syndrome (activating Gs-alpha mutation) - polyostotic fibrous dysplasia + café-au-lait spots + autonomous ovarian follicular cysts
  2. Granulosa cell tumor (estrogen-secreting)
  3. Adrenal causes - Congenital Adrenal Hyperplasia (CAH), virilizing adrenal tumor
  4. Exogenous estrogens
Causes in boys:
  1. Congenital Adrenal Hyperplasia
  2. hCG-secreting tumor (hepatoblastoma, germinoma)
  3. McCune-Albright syndrome
  4. Activating LH receptor mutations - Familial male-limited precocious puberty (testotoxicosis)
  5. Androgen-producing tumors (adrenal or testicular)
  6. Exogenous androgens

III. Variants (Incomplete Precocious Puberty)

TypeFeaturesManagement
Premature thelarcheUni/bilateral breast enlargement <2 yrs, no other sexual developmentBenign, self-limited; reassurance + follow-up
Premature adrenarche/pubarchePubic/axillary hair before age 8 in girls; must exclude nonclassic CAHUsually benign; monitor for PCOS, insulin resistance
Premature menarcheIsolated vaginal bleeding without other signsRule out foreign body, trauma, tumor
Premature adrenarche carries increased risk of PCOS, hyperinsulinemia, acanthosis nigricans, and dyslipidemia in later life, especially in those with low birth weight. - Berek & Novak's Gynecology

Evaluation of Precocious Puberty

  1. Complete medical, birth, and family history - timing of development
  2. Signs/symptoms of neurologic disease (headaches, visual changes, seizures)
  3. Physical exam with Tanner staging
  4. Look for associated signs: café-au-lait spots (McCune-Albright), abdominal mass
  5. Bone age (X-ray left hand/wrist) - advanced in true precocious puberty
  6. Initial hormonal workup:
    • Basal LH, FSH levels
    • Estradiol / testosterone
    • Thyroid function
    • 17-OHP (to exclude CAH)
  7. GnRH stimulation test: In true (central) precocious puberty, there is a pubertal LH response (LH >5 IU/L); in peripheral, LH remains suppressed
  8. Pelvic ultrasound: Uterine enlargement suggests true precocious puberty; ovarian cysts suggest McCune-Albright
  9. CNS MRI (brain): Mandatory in boys; in girls <6 years or if neurological signs present
  10. Uterine volume measurement (AP x longitudinal x transverse x 0.523) - most sensitive discriminator between premature thelarche and true precocious puberty

Management

A. Central (Gonadotropin-Dependent) Precocious Puberty

Drug of choice: GnRH agonists (Continuous/long-acting)
  • Mechanism: Continuous (non-pulsatile) GnRH agonist administration downregulates pituitary GnRH receptors → suppresses LH/FSH → lowers sex steroids
  • Leuprolide acetate (depot): 0.2-0.3 mg/kg IM every 4 weeks (most commonly used)
  • Histrelin implant: Annual subcutaneous implant
  • Triptorelin: Alternative depot formulation
  • Goals: Halt pubertal progression, allow normal height potential (by allowing growth plate closure to proceed slowly), improve psychological outcomes
  • Monitor: Growth velocity, bone age, LH response to stimulation, sex steroid levels
Treat underlying cause if structural (e.g., surgical excision of hypothalamic hamartoma if symptomatic)

B. Peripheral (Gonadotropin-Independent) Precocious Puberty

Treat the specific cause:
CauseTreatment
CAHGlucocorticoid replacement (hydrocortisone)
McCune-Albright (girls)Aromatase inhibitors (letrozole, anastrozole) or tamoxifen
Familial male-limited precocious puberty (boys)Cyproterone acetate + ketoconazole OR spironolactone + aromatase inhibitor
hCG-secreting tumorSurgical removal
Adrenal/gonadal tumorSurgery
Exogenous sex steroidsDiscontinue exposure
If secondary central activation occurs (peripheral → triggers HPG axis), add GnRH agonist.

Pseudohermaphroditism (5 marks)

Definition

A pseudohermaphrodite is an individual with discordance between phenotypic sex and gonadal sex (not between gonadal and genetic sex, as in true hermaphroditism).
  • Female pseudohermaphrodite: Genetic female (46,XX) with ovaries, but virilized (masculinized) external genitalia
  • Male pseudohermaphrodite: Genetic male (46,XY) with testes, but feminized external genitalia
A true hermaphrodite (ovotesticular DSD) has both ovarian and testicular tissue present. - Robbins Pathologic Basis of Disease

Female Pseudohermaphroditism (46,XX DSD)

Cause: Excess androgen exposure during fetal development
  1. Congenital Adrenal Hyperplasia (CAH) - most common cause; 21-hydroxylase deficiency (>90% of CAH)
  2. Maternal androgen-secreting tumors (e.g., Krukenberg tumor, luteoma of pregnancy)
  3. Exogenous androgens (e.g., progestins given to mother)
Features: Clitoral hypertrophy, labioscrotal fusion, common urogenital sinus; internal genitalia (uterus, ovaries, tubes) are normal

Male Pseudohermaphroditism (46,XY DSD)

Cause: Inadequate androgen action or production
  1. Androgen Insensitivity Syndrome (AIS):
    • Complete AIS (Testicular feminization): 46,XY, testes (intra-abdominal or inguinal), complete feminization of external genitalia, absent uterus and upper vagina, primary amenorrhea with well-developed breasts, scant/absent pubic & axillary hair, testosterone in male range
    • Partial AIS: Ambiguous genitalia
  2. 5-alpha reductase deficiency: Cannot convert testosterone to DHT → ambiguous genitalia at birth, virilization at puberty
  3. Leydig cell hypoplasia/aplasia: Impaired testosterone synthesis
  4. Inborn errors of testosterone biosynthesis (e.g., 17-beta-HSD deficiency)
  5. Partial gonadal dysgenesis (mixed gonadal dysgenesis - 45,X/46,XY)
Rare forms include persistent Müllerian duct syndrome (uterus/tubes persist in 46,XY males due to AMH deficiency or resistance).
Management principles:
  • Karyotype + hormone profile (LH, FSH, testosterone, DHT, 17-OHP, AMH)
  • If Y chromosome present: Gonadectomy to prevent gonadoblastoma (risk up to 30%)
  • Gender assignment (multidisciplinary team)
  • Hormone replacement as appropriate for assigned gender
  • Psychological support

Evaluation of Secondary Amenorrhea (5 marks)

Definition

Secondary amenorrhea is the absence of menstruation for 3 months in a woman who previously had regular cycles, or 6 months in a woman with irregular cycles.
Pregnancy must be excluded first in all women of reproductive age.

Causes (by anatomical compartment)

CompartmentCauses
UterineAsherman syndrome (post-traumatic synechiae), progestational agents
OvarianPCOS, Primary Ovarian Insufficiency (POI/premature ovarian failure), ovarian tumors, chemotherapy/radiation
AdrenalLate-onset CAH, Cushing syndrome, virilizing adrenal tumor
ThyroidHypothyroidism, hyperthyroidism
PituitaryHyperprolactinemia (prolactinoma), Sheehan syndrome, acquired hypopituitarism
HypothalamicFunctional hypothalamic amenorrhea (FHA) - excessive exercise, stress, weight loss, anorexia nervosa; infiltrative disease
IatrogenicAntipsychotics, antidepressants, antihypertensives, dopamine-altering drugs

Step-by-Step Evaluation

Step 1: Rule out pregnancy

  • Urine/serum beta-hCG

Step 2: History & Physical Examination

  • Menstrual history, recent weight changes, exercise, stress, galactorrhea, headaches, visual disturbances, hot flashes, hirsutism, acne
  • Tanner staging, thyroid enlargement, signs of hypoestrogenism or hyperandrogenism, BMI

Step 3: Initial laboratory workup (simultaneously)

  • TSH (thyroid disease)
  • Prolactin (hyperprolactinemia)
  • FSH/LH:
    • High FSH (>40 IU/L) → Primary Ovarian Insufficiency
    • Low/normal FSH with low LH → Hypothalamic or pituitary cause
    • High LH:FSH ratio (>2:1) with hyperandrogenism → PCOS

Step 4: Based on results

FindingNext Step
Elevated prolactinMRI of pituitary (exclude prolactinoma)
Elevated TSHTreat hypothyroidism (often corrects amenorrhea)
Elevated FSHKaryotype (<30 yrs); FMR1 (fragile X premutation); autoimmune panel
Normal FSH, no cause identifiedProgestin challenge test
Progestin challenge test:
  • Give medroxyprogesterone acetate (MPA) 10 mg/day x 5-10 days
  • Positive (withdrawal bleed): Anovulation with adequate estrogen (e.g., PCOS) → outflow tract intact
  • Negative (no bleed): Either outflow tract obstruction (Asherman syndrome) or hypoestrogenic state
If negative progestin challenge: give estrogen + progestin cycle
  • Bleed present → Asherman syndrome (confirm with hysteroscopy)
  • No bleed → Hypothalamic-pituitary failure (low estrogen)

Step 5: Further investigations

  • Pelvic ultrasound: Ovarian morphology (PCOS), endometrial thickness
  • Serum testosterone, DHEAS: If hirsutism/virilization present
  • 17-OHP: Exclude nonclassic CAH
  • Cortisol, dexamethasone suppression: If Cushing syndrome suspected
  • Brain MRI: Hypothalamic/pituitary lesion
  • Hysteroscopy/HSG: If Asherman syndrome suspected
  • Bone density (DEXA): If prolonged amenorrhea/hypoestrogenism confirmed

MTP Act (Medical Termination of Pregnancy Act) - India (5 marks)

Background

  • Originally enacted in 1971 as the Medical Termination of Pregnancy Act
  • Amended in 2002, 2003, and 2021
  • 2021 Amendment is the most significant recent revision
  • Aim: Reduce maternal morbidity and mortality from unsafe abortions; balance ethical, legal, and medical concerns
  • The Essentials of Forensic Medicine and Toxicology, 36th ed. (2026)

Key Definitions

  1. Registered Medical Practitioner (RMP): Practitioner registered under Indian Medical Council Act with training/experience in obstetrics and gynecology
  2. Termination: Medically induced expulsion of fetus prior to viability (<20-24 weeks depending on amendment)
  3. Minor: Girl <18 years - requires written guardian consent
  4. Substantial risk: Physical/mental abnormality, fetal anomaly, rape/incest, contraceptive failure (extended to unmarried women by 2021 Amendment)

Permissible Time Limits (Post-2021 Amendment)

Gestational AgeConditionsRMP Required
Up to 20 weeksStandard grounds (risk to life/health, rape, contraceptive failure, fetal anomaly)1 RMP
20-24 weeksSpecial categories only: rape survivors, minors, women with mental illness, fetal anomalies, disabled women2 RMPs
Beyond 24 weeksSubstantial fetal anomaly onlyMedical Board approval required

Grounds for Termination (Section 3)

  1. Risk to life of the pregnant woman
  2. Grave physical or mental injury to the woman
  3. Substantial fetal abnormality - incompatible with life or associated with high morbidity
  4. Pregnancy due to rape or incest (presumed to cause grave mental injury)
  5. Failure of contraception - in married or unmarried women (2021 Amendment extended this to unmarried women)

2021 Amendment - Key Changes

  1. Upper gestational limit increased from 20 to 24 weeks for special categories
  2. Removal of upper gestation limit for fetal anomalies - subject to Medical Board approval
  3. Unmarried women included in contraceptive failure clause
  4. Privacy clause: No RMP shall reveal the woman's identity except to a person authorized by law; violation is punishable with fine/imprisonment
  5. Medical Board: Mandatory for cases beyond 24 weeks with severe fetal anomalies; consists of gynecologist, radiologist/sonologist, pediatrician, and other notified members

Approved Places for MTP (Section 4)

  • Government hospitals
  • Private hospitals/clinics approved by government
  • Must have: aseptic surgical environment, emergency resuscitation, blood transfusion, post-procedure care

Consent Requirements

CategoryConsent Required
Adult woman ≥18 yearsHer own written consent only
Minor <18 yearsWritten consent of guardian
Mentally ill womanWritten consent of guardian
Married womanHer own consent only (no spousal consent needed)

Techniques of MTP

Gestational AgeMethod
Up to 9 weeksMedical abortion - Mifepristone + Misoprostol
9-12 weeksManual Vacuum Aspiration (MVA) or Electric Vacuum Aspiration (EVA)
12-20 weeksDilatation and Evacuation (D&E)
>20 weeksInduction abortion, intact D&E, or hysterotomy depending on viability

Documentation Required

  • Form C: Consent form
  • Form I: RMP opinion
  • Form II: Monthly report of MTPs conducted
  • Records maintained for 5 years; confidentiality strictly maintained

Ethical Principles Underlying the Act

  1. Autonomy - woman's right over reproductive health
  2. Non-maleficence - abortions performed safely
  3. Beneficence - protection from unsafe practices
  4. Justice - equitable access for marginalized groups (rape victims, minors, women with fetal anomalies)
  5. Confidentiality - strict privacy of patient identity
Sources: Berek & Novak's Gynecology | Harrison's Principles of Internal Medicine 22E | Robbins, Cotran & Kumar Pathologic Basis of Disease | Tietz Textbook of Laboratory Medicine 7E | Katzung's Basic and Clinical Pharmacology 16E | The Essentials of Forensic Medicine and Toxicology 36E (2026)
This is a shared conversation. Sign in to Orris to start your own chat.